PMID- 19383973 OWN - NLM STAT- MEDLINE DCOM- 20090918 LR - 20211203 IS - 1937-9145 (Electronic) IS - 1945-0877 (Linking) VI - 2 IP - 67 DP - 2009 Apr 21 TI - Focus Issue: demystifying mTOR signaling. PG - eg5 LID - 10.1126/scisignal.267eg5 [doi] AB - The mammalian target of rapamycin (mTOR) is a master integrator of cell energy state, nutrient status, and growth factor stimulation. This kinase is part of two distinct complexes, mTORC1 and mTORC2, and the network that regulates these two complexes is interconnected with distinct and overlapping inputs and outputs. Research published in Science Signaling has revealed new connections between epidermal growth factor receptors and the mTOR pathway, and new insight into the roles of mTOR signaling in vascular disease. The Perspectives in this issue highlight how new pharmacological tools and the ability to knock down the function of complex-specific subunits are providing new insight into the regulation and functions of these complexes in physiological contexts, as well as providing new avenues for therapeutic intervention in diseases associated with aberrant activity of these complexes. FAU - Gough, Nancy R AU - Gough NR LA - eng PT - Editorial PT - Introductory Journal Article DEP - 20090421 PL - United States TA - Sci Signal JT - Science signaling JID - 101465400 RN - 0 (Immunosuppressive Agents) RN - EC 2.7.- (Protein Kinases) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - Animals MH - Humans MH - Immunosuppressive Agents/pharmacology MH - Protein Kinases/*metabolism MH - Signal Transduction/drug effects/*physiology MH - Sirolimus/pharmacology MH - TOR Serine-Threonine Kinases EDAT- 2009/04/23 09:00 MHDA- 2009/09/19 06:00 CRDT- 2009/04/23 09:00 PHST- 2009/04/23 09:00 [entrez] PHST- 2009/04/23 09:00 [pubmed] PHST- 2009/09/19 06:00 [medline] AID - scisignal.267eg5 [pii] AID - 10.1126/scisignal.267eg5 [doi] PST - epublish SO - Sci Signal. 2009 Apr 21;2(67):eg5. doi: 10.1126/scisignal.267eg5.